## Supplementary Material

**Supplementary Table S1.** GEO accession number, tumor stage, location and previous treatment details for the colorectal cancer samples from the Expression Project for Oncology (expO) for which microarray data were retrieved.

GEO accession	Stage	Location	Prior therapy
GSM38075	Α	Colon	None
GSM53055	Α	Colon	None
GSM53087	Α	Rectosigmoid	None
GSM76530	Α	Colon	None
GSM76576	Α	Colon	None
GSM76629	Α	Colon	None
GSM88982	Α	Rectum	None
GSM89044	Α	Colon	None
GSM89074	Α	Rectum	None
GSM89095	А	Rectum	None
GSM102479	Α	Rectosigmoid	None
GSM102517	Α	Rectosigmoid	None
GSM102549	Α	Colon	None
GSM102561	Α	Colon	None
GSM102572	Α	Colon	None
GSM102579	Α	Colon	None
GSM117577	Α	Rectum	None
GSM117652	Α	Rectosigmoid	None
GSM117656	Α	Colon	None
GSM117672	Α	Colon	None
GSM117676	Α	Colon	None
GSM117681	Α	Colon	None
GSM117699	А	Rectosigmoid	None
GSM117707	Α	Rectum	None
GSM117720	А	Colon	None
GSM137922	A	Colon	None
GSM138022	А	Colon	None
GSM152602	Α	Colon	None

GSM152632	Α	Colon	None
GSM152666	Α	Colon	None
GSM152684	Α	Colon	None
GSM152725	Α	Colon	None
GSM179820	Α	Colon	None
GSM179838	Α	Colon	None
GSM179844	Α	Colon	None
GSM179859	Α	Colon	None
GSM179889	Α	Colon	None
GSM179894	Α	Rectosigmoid	None
GSM203625	Α	Colon	None
GSM203673	Α	Colon	None
GSM203687	Α	Colon	None
GSM203788	Α	Rectum	None
GSM38077	В	Rectosigmoid	None
GSM38098	В	Rectosigmoid Junction	None
GSM46878	В	Colon	None
GSM46895	В	Colon	None
GSM46930	В	Colon	None
GSM53106	В	Colon	None
GSM53113	В	Colon	None
GSM53178	В	Colon	None
GSM76520	В	Colon	None
GSM76522	В	Colon	None
GSM76555	В	Colon	None
GSM76573	В	Colon	None
GSM76583	В	Colon	None
GSM76607	В	Colon	None
GSM76608	В	Colon	None
GSM76617	В	Colon	None
GSM76618	В	Colon	None
GSM88945	В	Colon	None
GSM88963	В	Colon	None
GSM88999	В	Colon	None
GSM89004	В	Colon	None

GSM89007	В	Colon	None
GSM89026	В	Colon	None
GSM89047	В	Colon	None
GSM89049	В	Colon	None
GSM89052	В	Colon	None
GSM89061	В	Colon	None
GSM89062	В	Colon	None
GSM102429	В	Colon	None
GSM102460	В	Colon	None
GSM102462	В	Rectosigmoid	None
GSM102485	В	Colon	None
GSM102486	В	Rectum	None
GSM102516	В	Colon	None
GSM102519	В	Colon	None
GSM102539	В	Rectosigmoid	None
GSM102551	В	Colon	None
GSM102559	В	Colon	None
GSM102577	В	Colon	None
GSM102581	В	Colon	None
GSM117635	В	Colon	None
GSM117649	В	Colon	None
GSM117662	В	Colon	None
GSM117709	В	Colon	None
GSM117728	В	Colon	None
GSM117742	В	Colon	None
GSM137947	В	Colon	None
GSM137949	В	Colon	None
GSM137967	В	Colon	None
GSM138015	В	Colon	None
GSM138021	В	Rectosigmoid	None
GSM138044	В	Colon	None
GSM138048	В	Colon	None
GSM138050	В	Colon	None
GSM138052	В	Colon	None
GSM152573	В	Colon	None

GSM152591	В	Colon	None
GSM152604	В	Hepatic Flexure	None
GSM152610	В	Colon	None
GSM152614	В	Colon	None
GSM152630	В	Rectum	None
GSM152658	В	Colon	None
GSM152762	В	Colon	None
GSM152780	В	Colon	None
GSM152799	В	Colon	None
GSM179803	В	Colon	None
GSM179804	В	Colon	None
GSM179839	В	Colon	None
GSM179856	В	Cecum	None
GSM179860	В	Colon	None
GSM179887	В	Colon	None
GSM179897	В	Colon	None
GSM179899	В	Colon	None
GSM203642	В	Colon	None
GSM203667	В	Colon	None
GSM203700	В	Colon	None
GSM203755	В	Colon	None
GSM203782	В	Colon	None
GSM231879	В	Colon	None
GSM231905	В	Colon	None
GSM231908	В	Colon	None
GSM231956	В	Colon	None
GSM231988	В	Colon	None
GSM38055	С	Colon	None
GSM38074	С	Colon	None
GSM38105	С	Colon	None
GSM38107	С	Colon	None
GSM46841	С	Colon	None
GSM46861	С	Colon	None
GSM46887	С	Colon	None
GSM46921	С	Colon	None

GSM46931	С	Colon	None
GSM46972	С	Rectosigmoid	None
GSM76501	С	Colon	None
GSM76519	С	Colon	None
GSM76526	С	Colon	None
GSM76546	С	Rectosigmoid	None
GSM76548	С	Colon	None
GSM76575	С	Rectum	None
GSM76639	С	Colon	None
GSM88968	С	Colon	None
GSM89037	С	Colon	None
GSM89040	С	Colon	None
GSM89053	С	Colon	None
GSM89069	С	Colon	None
GSM89075	С	Rectosigmoid Colon	None
GSM89090	С	Colon	None
GSM89098	С	Colon	None
GSM102431	С	Colon	None
GSM102436	С	Colon	None
GSM102524	С	Colon	None
GSM102540	С	Colon	None
GSM117642	С	Colon	None
GSM117673	С	Colon	None
GSM117702	С	Rectosigmoid	None
GSM117738	С	Colon	None
GSM117746	С	Colon	None
GSM138007	С	Colon	None
GSM138018	С	Colon	None
GSM152572	С	Rectosigmoid	None
GSM152613	С	Colon	None
GSM152664	С	Colon	None
GSM152695	С	Colon	None
GSM152703	С	Rectosigmoid	None
GSM152712	С	Rectum	None
GSM152714	С	Colon	None

GSM152730	С	Colon	None
GSM179793	С	Colon	None
GSM179795	С	Colon	None
GSM179831	С	Colon	None
GSM179845	С	Rectum	None
GSM179858	С	Rectum	None
GSM179880	С	Colon	None
GSM179882	С	Colon	None
GSM179908	С	Colon	None
GSM179920	С	Rectum	None
GSM179930	С	Colon	None
GSM179937	С	Colon	None
GSM203627	С	Colon	None
GSM203640	С	Colon	None
GSM203645	С	Colon	None
GSM203653	С	Colon	None
GSM203674	С	Colon	None
GSM203684	С	Colon	None
GSM203702	С	Colon	None
GSM203705	С	Colon	None
GSM203728	С	Colon	None
GSM203733	С	Colon	None
GSM203780	С	Rectosigmoid	None
GSM231875	С	Colon	None
GSM231915	С	Colon	None
GSM231928	С	Colon	None
GSM231936	С	Colon	None
GSM231958	С	Colon	None
GSM231961	С	Colon	None
GSM231987	С	Rectum	None
GSM38061	D	Colon	None
GSM38089	D	Colon	None
GSM53132	D	Rectosigmoid	None
GSM76529	D	Colon	None
GSM76571	D	Rectum	None

GSM76605	D	Colon	None
GSM88994	D	Colon	None
GSM89103	D	Colon	None
GSM102472	D	Colon	None
GSM102513	D	Colon	None
GSM102533	D	Colon	None
GSM102535	D	Rectosigmoid	None
GSM117760	D	Colon	None
GSM137985	D	Rectosigmoid	None
GSM137998	D	Colon	None
GSM152692	D	Colon	None
GSM152710	D	Rectosigmoid	None
GSM152750	D	Rectosigmoid	None
GSM179778	D	Colon	None
GSM179805	D	Colon	None
GSM179867	D	Colon	None
GSM179925	D	Colon	None
GSM179928	D	Colon	None
GSM179948	D	Colon	None
GSM203657	D	Colon	None
GSM203688	D	Colon	None
GSM203691	D	Rectosigmoid	None
GSM203743	D	Colon	None
GSM203763	D	Colon	None
GSM231904	D	Colon	None
GSM231959	D	Colon	None
GSM231964	D	Colon	None
GSM38078	Deposit	Liver (primary: colon)	None
GSM46828	Deposit	Liver or Omentum (primary: colon)	Chemotherapy
GSM46946	Deposit	Adrenal gland (primary: colon)	None
GSM46970	Deposit	Liver (primary: rectosigmoid)	Chemotherapy
GSM46971	Deposit	Liver (primary: colon)	None
GSM76540	Deposit	Omentum (primary: colon)	None
GSM76625	Deposit	Abdominal wall mass (primary: rectum)	Chemotherapy
GSM88946	Deposit	Liver (primary: colon)	Chemotherapy

GSM89001	Deposit	Ovary (primary: rectosigmoid)	None
GSM89030	Deposit	Liver (primary: colon)	Chemotherapy
GSM89036	Deposit	Ovary (primary: colon)	Chemotherapy
GSM102484	Deposit	Small intestine (primary: colon)	Chemotherapy
GSM137897	Deposit	Liver (primary: rectosigmoid)	None
GSM137933	Deposit	Liver (primary: colon)	Chemotherapy
GSM137935	Deposit	Liver (primary: rectum)	None
GSM137976	Deposit	Bladder (primary: colon)	None
GSM138043	Deposit	Liver (primary: colon)	Chemotherapy
GSM138047	Deposit	Lung (primary: colon)	Chemotherapy
GSM152592	Deposit	Lung (primary: colon)	Chemotherapy
GSM152612	Deposit	Liver (primary: colon)	None
GSM152619	Deposit	Small bowel (primary: colon)	Chemotherapy
GSM152626	Deposit	Liver (primary: colon)	None
GSM152708	Deposit	Liver (primary: colon)	Chemotherapy
GSM152709	Deposit	Ovary (primary: colon)	None
GSM152760	Deposit	Liver (primary: colon)	Chemotherapy
GSM152765	Deposit	Liver (primary: colon)	None
GSM179840	Deposit	Liver (primary: colon)	Chemotherapy
GSM179865	Deposit	Liver (primary: colon)	Chemotherapy
GSM203775	Deposit	Liver (primary: colon)	None
GSM231883	Deposit	Liver (primary: rectum)	Chemotherapy

**Supplementary Table S2.** Details of the 128 reproducible metastasis-associated genes (163 probe sets) identified across three cohorts of early-stage and metastatic colorectal cancers.

<sup>&</sup>lt;sup>5</sup> Fold change (on log2 scale) = the median log2 value of the metastatic cancer samples subtracted the median log2 value of the early-stage cancer samples

			Cohort 1 <sup>1</sup>		Cohort 2 <sup>2</sup>		Cohort 3 <sup>3</sup>	
Affymetr ix ID	Gene symbol	Accession number	q-value (%) <sup>4</sup>	Fold change⁵	q-value (%)	Fold change	q-value (%)	Fold change
209875_ s_at	SPP1	M83248	0.00	1.80	0.00	2.46	0.00	3.32
219054_ at	C5orf23	NM_024563	0.00	1.14	0.00	1.37	0.00	1.80
235944_ at	HMCN1	BF446673	0.00	1.17	3.54	0.85	0.00	1.44
219087_ at	ASPN	NM_017680	1.10	1.11	3.54	1.33	0.05	1.87
202436_ s_at	CYP1B1	AU144855	3.59	0.46	0.00	1.48	0.00	2.32
229479_ at	LOC64632 4	Al739132	3.59	1.40	0.00	1.01	0.00	1.42
230175_ s_at	DCBLD2	AA805633	3.59	0.41	0.00	0.89	0.00	0.81
201125_ s_at	ITGB5	NM_002213	2.74	0.29	1.57	0.38	0.26	0.38
228176_ at	C9orf47	AA534817	2.74	0.41	2.69	0.72	0.00	0.94
228224_ at	PRELP	AA573140	1.10	0.87	5.98	1.88	0.00	2.86

<sup>&</sup>lt;sup>1</sup> Cohort 1 consists of 44 stage A and 61 stage D colorectal cancers from this study

<sup>&</sup>lt;sup>2</sup> Cohort 2 consists of 42 stage A and 32 primary stage D colorectal cancers from expO

<sup>&</sup>lt;sup>3</sup> Cohort 3 consists of 42 stage A colorectal cancers and 30 metastectomy specimens from expO

<sup>&</sup>lt;sup>4</sup> q-values from Significance Analysis of Microarrays (SAM) with a false-discovery rate (FDR) of 10%

224396_ s_at	ASPN	AF316824	1.10	1.22	5.98	1.16	0.26	1.50
229669_ at	LOC33926 0	AA166965	3.59	0.54	1.57	0.59	0.16	0.56
228335_ at	CLDN11	AW264204	3.59	0.51	1.94	0.98	0.00	1.68
218718_ at	PDGFC	NM_016205	3.59	0.60	1.94	0.75	0.00	0.96
203640_ at	MBNL2	BE328496	1.10	0.33	8.38	0.35	0.26	0.44
205422_ s_at	ITGBL1	NM_004791	5.65	1.19	0.00	1.56	0.00	2.11
213352_ at	TMCC1	AB018322	5.65	0.29	0.00	0.56	0.00	0.54
214927_ at	ITGBL1	AL359052	5.65	0.57	0.00	1.00	0.00	1.38
217949_ s_at	VKORC1	NM_024006	2.74	0.31	5.98	0.25	0.00	0.85
205713_ s_at	COMP	NM_000095	5.65	0.95	0.00	1.89	0.88	1.37
231317_ at	TSNARE1	AI741779	2.74	0.75	2.69	0.40	4.32	0.35
227112_ at	TMCC1	AW270037	5.65	0.31	1.57	0.35	0.00	0.55
204619_ s_at	VCAN	BF590263	5.65	0.57	1.57	1.17	0.16	0.90
203083_ at	THBS2	NM_003247	5.65	1.07	1.94	1.44	0.00	1.79
235408_ x_at	ZNF117	AW058673	5.65	0.52	1.57	0.55	0.53	0.57
222379_ at	KCNE4	Al002715	5.65	0.35	2.69	0.89	0.00	0.90
227566_ at	HNT	AW085558	5.65	1.04	1.94	1.30	0.88	0.76
226930_ at	FNDC1	Al345957	5.65	1.10	2.69	1.16	0.26	1.16
228850_ s_at	SLIT2	Al963304	5.65	0.81	2.69	0.61	0.26	0.58
209581_ at	HRASLS3	BC001387	3.59	0.52	5.98	0.60	1.36	0.72
226237_ at	COL8A1	AL359062	3.59	1.43	1.57	1.40	5.83	0.75

217428_ s_at	COL10A1	X98568	3.59	1.81	0.00	2.61	7.49	1.51
212464_ s_at	FN1	X02761	5.65	0.94	3.54	1.43	0.00	2.22
226137_ at	ZFHX3	Al288759	5.65	0.34	2.69	0.34	0.88	0.24
205941_ s_at	COL10A1	Al376003	3.59	1.45	1.94	1.91	5.83	1.26
1557080 _s_at	ITGBL1	AI753143	7.72	0.70	0.00	0.81	0.00	1.19
202435_ s_at	CYP1B1	AU154504	7.72	0.62	0.00	0.99	0.00	1.61
213351_ s_at	TMCC1	AB018322	7.72	0.25	0.00	0.41	0.00	0.65
208626_ s_at	VAT1	BC001913	1.10	0.51	5.98	0.49	7.49	0.46
210511_ s_at	INHBA	M13436	7.72	0.96	0.00	1.43	0.53	1.27
201162_ at	IGFBP7	NM_001553	7.72	0.49	1.57	0.59	0.00	0.71
211709_ s_at	CLEC11A	BC005810	5.65	0.62	1.57	0.76	4.32	0.67
200665_ s_at	SPARC	NM_003118	7.72	0.41	1.57	0.95	0.26	0.57
205381_ at	LRRC17	NM_005824	5.65	0.48	5.98	0.39	0.00	0.73
211597_ s_at	HOP	AB059408	5.65	1.08	5.98	0.73	0.05	1.14
204468_ s_at	TIE1	NM_005424	7.72	0.68	1.94	0.86	0.05	1.28
37022_at	PRELP	U41344	7.72	0.40	1.94	0.45	0.05	0.76
227121_ at	N/A	BF476076	5.65	0.33	5.98	0.33	0.16	0.64
211071_ s_at	MLLT11	BC006471	3.59	0.35	5.98	0.32	4.32	0.30
226497_ s_at	FLT1	AA149648	7.72	0.45	1.94	0.49	0.16	0.54
210517_ s_at	AKAP12	AB003476	2.74	1.13	8.38	0.77	4.32	0.54
201150_ s_at	TIMP3	NM_000362	2.74	0.97	8.38	0.93	4.32	0.69

040007								
212667_ at	SPARC	AL575922	7.72	0.52	2.69	0.99	0.05	1.15
224911_ s_at	DCBLD2	AA722799	7.72	0.30	1.94	0.58	0.88	0.69
236297_ at	N/A	Al420817	5.65	0.55	4.55	0.64	3.12	0.49
211719_ x_at	FN1	BC005858	7.72	0.89	3.54	1.37	0.00	2.06
216442_ x_at	FN1	AK026737	7.72	0.91	3.54	1.14	0.00	1.97
210004_ at	OLR1	AF035776	7.72	0.81	3.54	0.88	0.00	1.32
209894_ at	LEPR	U50748	7.72	0.51	3.54	0.66	0.00	0.97
223279_ s_at	UACA	AF322916	7.72	0.24	3.54	0.26	0.05	0.44
1553530 _a_at	ITGB1	NM_033669	5.65	0.40	5.98	0.44	2.08	0.45
210495_ x_at	FN1	AF130095	7.72	0.89	4.55	1.20	0.00	1.99
225566_ at	NRP2	Al819729	7.72	1.12	4.55	0.55	0.00	1.08
204589_ at	NUAK1	NM_014840	5.65	0.65	8.38	0.52	0.53	0.56
210809_ s_at	POSTN	D13665	7.72	1.10	3.54	1.16	1.36	0.95
202133_ at	WWTR1	BF674349	7.72	0.53	3.54	0.90	1.36	0.91
219179_ at	DACT1	NM_016651	5.65	0.46	5.98	0.79	3.12	0.53
213413_ at	STON1	BG434174	3.59	0.40	4.55	0.82	9.75	0.29
219922_ s_at	LTBP3	NM_021070	7.72	0.37	5.98	0.54	0.26	0.78
204223_ at	PRELP	NM_002725	7.72	0.63	5.98	0.68	0.26	0.99
225450_ at	AMOTL1	Al433831	7.72	0.49	5.98	0.57	0.26	0.94
201560_ at	CLIC4	NM_013943	5.65	0.66	4.55	0.55	5.83	0.51
210078_ s_at	KCNAB1	L39833	5.65	0.47	8.38	0.94	2.08	0.81

1555778 _a_at	POSTN	AY140646	7.72	1.11	5.98	1.04	0.88	1.09
213125_ at	OLFML2B	AW007573	7.72	0.40	2.69	0.77	4.32	0.52
213656_ s_at	KLC1	BF593594	7.72	0.28	5.98	0.25	1.36	0.23
227529_ s_at	AKAP12	BF511276	2.74	0.98	8.38	0.65	9.75	0.45
225021_ at	ZNF532	AA861416	5.65	0.33	2.69	0.36	9.75	0.47
214770_ at	MSR1	Al299239	7.72	0.59	8.38	0.62	0.00	1.52
209747_ at	TGFB3	J03241	7.72	0.40	8.38	0.41	0.26	0.59
212488_ at	COL5A1	N30339	7.72	0.54	8.38	0.49	1.36	0.69
225381_ at	LOC39995 9	AW162210	3.59	0.76	8.38	0.78	9.75	0.57
202766_ s_at	FBN1	NM_000138	7.72	0.72	5.98	0.91	4.32	0.52
203238_ s_at	NOTCH3	NM_000435	5.65	0.38	5.98	0.59	9.75	0.61
226364_ at	HIP1	AU145049	7.72	0.39	1.94	0.70	9.75	0.46
226997_ at	ADAMTS1 2	W74476	7.72	0.51	3.54	0.63	9.75	0.46
227530_ at	AKAP12	BF511276	5.65	0.59	8.38	0.71	9.75	0.53
225946_ at	RASSF8	BG484552	7.72	0.47	8.38	0.63	7.49	0.58
1558027 _s_at	PRKAB2	AL552001	7.72	0.37	8.38	0.31	7.49	0.20
207076_ s_at	ASS1	NM_000050	1.41	-0.39	1.57	-0.95	1.36	-0.37
224240_ s_at	CCL28	AF266504	1.41	-0.91	3.54	-0.71	0.00	-0.85
211367_ s_at	CASP1	U13699	0.00	-1.12	5.98	-0.70	1.36	-0.48
209374_ s_at	IGHM	BC001872	1.41	-1.65	4.55	-2.07	0.00	-2.31
205267_ at	POU2AF1	NM_006235	1.41	-0.97	4.55	-1.20	0.05	-1.69

205891_ at	ADORA2B	NM_000676	1.41	-0.38	4.55	-0.73	0.16	-0.72
217378_ x_at	IGKV1OR 2-108	X51887	1.41	-1.33	4.55	-1.46	0.16	-2.11
214836_ x_at	IGKC	BG536224	1.41	-1.18	4.55	-1.13	0.16	-1.46
218096_ at	AGPAT5	NM_018361	1.41	-0.50	5.98	-0.40	0.05	-0.81
215949_ x_at	IGHM	BF002659	2.74	-1.19	3.54	-1.52	0.00	-2.00
226147_ s_at	PIGR	AA838075	2.74	-0.85	3.54	-1.37	0.00	-4.32
202659_ at	PSMB10	NM_002801	1.41	-0.47	3.54	-0.57	3.12	-0.40
214916_ x_at	IL8	BG340548	2.74	-1.07	4.55	-1.60	0.00	-1.78
211881_ x_at	IGLJ3	AB014341	2.74	-0.85	4.55	-1.18	0.05	-1.33
216576_ x_at	NTN2L	AF103529	2.74	-1.24	4.55	-1.85	0.16	-1.84
209970_ x_at	CASP1	M87507	0.00	-0.68	8.38	-0.62	2.08	-0.51
216207_ x_at	IGKV1D-13	AW408194	1.41	-0.95	8.38	-1.26	0.16	-1.56
205049_ s_at	CD79A	NM_001783	2.74	-0.59	5.98	-0.81	0.00	-1.47
211645_ x_at	N/A	M85256	2.74	-1.07	5.98	-1.26	0.16	-2.21
234366_ x_at	IGL@	AF103591	2.74	-0.77	5.98	-0.76	0.26	-1.15
217480_ x_at	HLA-C	M20812	2.74	-1.08	5.98	-0.82	0.26	-1.33
238750_ at	N/A	AW083576	3.59	-0.79	4.55	-0.99	0.00	-1.91
217157_ x_at	N/A	AF103530	3.59	-0.89	4.55	-0.86	0.16	-1.49
209208_ at	MPDU1	AF059752	1.41	-0.29	8.38	-0.47	0.88	-0.56
211368_ s_at	CASP1	U13700	0.00	-0.86	8.38	-0.46	4.32	-0.37
214440_ at	NAT1	NM_000662	3.59	-0.54	5.98	-0.72	0.00	-0.96

211366_ x_at	CASP1	U13698	1.41	-0.77	8.38	-0.58	2.08	-0.53
238725_ at	IRF1	AW392551	1.41	-0.80	3.54	-0.68	7.49	-0.45
234884_ x_at	N/A	L21961	2.74	-0.84	8.38	-0.92	0.05	-1.12
221286_ s_at	MGC29506	NM_016459	2.74	-1.17	8.38	-1.03	0.05	-1.48
205476_ at	CCL20	NM_004591	2.74	-0.90	8.38	-1.14	0.16	-1.48
212592_ at	IGJ	AV733266	5.65	-0.79	3.54	-1.99	0.00	-3.28
204213_ at	PIGR	NM_002644	5.65	-1.03	3.54	-2.03	0.00	-2.28
226499_ at	NRARP	W72331	5.65	-0.30	3.54	-0.53	0.00	-1.09
214214_ s_at	C1QBP	AU151801	5.65	-0.29	3.54	-0.49	0.16	-0.61
211798_ x_at	IGLJ3	AB001733	3.59	-0.96	8.38	-0.98	0.00	-1.45
215176_ x_at	NTN2L	AW404894	3.59	-0.65	8.38	-1.08	0.16	-2.15
209397_ at	ME2	BC000147	2.74	-0.30	4.55	-0.50	5.83	-0.25
206641_ at	TNFRSF17	NM_001192	5.65	-1.03	4.55	-1.00	0.00	-1.50
216557_ x_at	IFI6	U92706	5.65	-1.10	4.55	-1.52	0.00	-1.41
221651_ x_at	IGKC	BC005332	5.65	-0.34	4.55	-0.60	0.26	-1.23
229568_ at	MOBKL2B	Al692878	7.72	-0.24	1.57	-0.59	0.00	-0.73
219727_ at	DUOX2	NM_014080	5.65	-1.47	5.98	-2.35	0.00	-2.92
217281_ x_at	IL8	AJ239383	5.65	-1.10	5.98	-1.47	0.00	-2.13
221671_ x_at	IGKC	M63438	5.65	-0.34	5.98	-0.66	0.16	-1.28
_	CTA-246H3	AL022324	5.65	-0.74	5.98	-0.88	0.26	-1.12
214777_ at	N/A	BG482805	5.65	-1.55	5.98	-1.95	0.53	-1.72

209040_ s_at	PSMB8	U17496	5.65	-0.39	4.55	-0.31	3.12	-0.27
216542_ x_at	IGHA1	AJ275355	7.72	-0.72	3.54	-1.34	0.00	-1.50
224027_ at	CCL28	AF110384	5.65	-0.70	8.38	-1.04	0.00	-1.42
229070_ at	C6orf105	AA470369	5.65	-1.07	8.38	-1.83	0.05	-2.09
211641_ x_at	N/A	L06101	7.72	-0.67	4.55	-0.93	0.00	-1.30
204301_ at	KBTBD11	NM_014867	7.72	-0.46	4.55	-0.68	0.00	-0.99
221841_ s_at	KLF4	BF514079	7.72	-0.42	4.55	-0.72	0.05	-0.80
211647_ x_at	IGHG1	L14454	7.72	-0.30	4.55	-0.72	0.53	-0.64
235350_ at	C4orf19	Al935586	7.72	-0.53	4.55	-0.73	0.53	-0.66
216829_ at	NTN2L	X72475	5.65	-1.03	8.38	-0.79	0.88	-1.27
203110_ at	PTK2B	U43522	7.72	-0.53	3.54	-0.39	2.08	-0.35
214433_ s_at	SELENBP1	NM_003944	7.72	-1.04	5.98	-0.86	0.00	-1.49
226319_ s_at	THOC4	AF047002	7.72	-0.35	5.98	-0.47	0.16	-0.65
227014_ at	ASPHD2	BE550881	5.65	-0.43	5.98	-0.49	4.32	-0.34
209569_ x_at	D4S234E	NM_014392	5.65	-0.34	5.98	-0.39	4.32	-0.50
225667_ s_at	FAM84A	Al601101	7.72	-0.41	5.98	-0.81	0.26	-1.16
211635_ x_at	IGHV1-69	M24670	7.72	-0.96	5.98	-1.38	0.53	-1.12
205242_ at	CXCL13	NM_006419	5.65	-1.55	3.54	-1.17	7.49	-0.82
219148_ at	PBK	NM_018492	7.72	-0.66	8.38	-0.82	0.05	-1.26
219450_ at	C4orf19	NM_018302	7.72	-0.28	8.38	-0.71	0.16	-0.71
209138_ x_at	IGL@	M87790	7.72	-0.61	8.38	-1.20	0.26	-1.35

214677_ x_at	IGLJ3	X57812	7.72	-0.44	8.38	-0.89	0.26	-1.12
1555779 _a_at	CD79A	M74721	7.72	-0.48	8.38	-0.59	0.26	-0.49
210885_ s_at	TRIM15	AF220133	7.72	-0.55	8.38	-0.52	0.53	-0.59
216430_ x_at	IGL@	AF043586	7.72	-1.69	8.38	-1.58	2.08	-0.83
225053_ at	CNOT7	W94952	7.72	-0.38	8.38	-0.23	5.83	-0.19
204279_ at	PSMB9	NM_002800	7.72	-0.42	8.38	-0.50	7.49	-0.55

**Supplementary Table S3.** Comparison of gene expression changes between the two main groups of stage B or stage C colorectal cancers resulting from unsupervised clustering using our set of 128 metastasis-associated genes (163 probe sets) with those observed between early-stage and metastatic colorectal cancers.

Clustering was performed separately for 95 stage B and 93 stage C colorectal cancers from this study, and 83 stage B and 73 stage C colorectal cancers from expO. Up- or down-regulation in median gene expression between the two main resulting groups was compared to that observed between early-stage and metastatic colorectal cancers using Pearson's chi-squared test.

	Metastatic v	s. early-stage	
	Up-regulated	Down-regulated	P value
Stage B – this study: Group 2 vs. 1			
Up-regulated	89 (54.6%)	2 (1.2%)	< 0.001
Down-regulated	0 (0.0%)	72 (44.2%)	
Stage C – this study: Group 1 vs. 2			
Up-regulated	88 (54.0%)	2 (1.2%)	< 0.001
Down-regulated	1 (0.6%)	72 (44.2%)	
Stage B – expO: Group 2 vs. 1			
Up-regulated	89 (54.6%)	4 (2.5%)	< 0.001
Down-regulated	0 (0.0%)	70 (42.9%)	
Stage C – expO: Group 1 vs. 2			
Up-regulated	89 (54.6%)	0 (0.0%)	< 0.001
Down-regulated	0 (0.0%)	74 (45.4%)	

**Supplementary Table S4.** Cox proportional-hazard analysis of the risk of recurrence as a first event in 95 stage B and 93 stage C colorectal cancer patients for individual probe sets of our 128 metastasis-associated genes.

<sup>1</sup>Hazard ratios are adjusted for adjuvant treatment.

<sup>2</sup>P values are adjusted using the Benjamini-Hochberg False Discovery Rate multiple testing correction.

P values less than 0.05 are shown in bold. Genes with unadjusted P<0.05 in both stage B and C patients are shown in bold.

Affymetri x ID	Gene symbol	Accessi on number	Stage B				Stage		Metastatic vs. early-stage		
			Hazard ratio <sup>1</sup> (95% CI)		P val ue	P val ue <sup>2</sup>	Hazard ratio <sup>1</sup> (95% CI)		P val ue	P val ue <sup>2</sup>	
209875_s _at	SPP1	M83248	1.21	(0.82-1.7 7)	0.3 40	0.44 0	1.17	(0.93-1.4 6)	0.1 80	0.36 2	upregulated
219054_a t	C5orf23	NM_024 563	1.56	(1.00-2.4 3)	0.0 51	0.16 3	1.28	(1.00-1.6 3)	0.0 54	0.31 3	upregulated
235944_a t	HMCN1	BF4466 73	1.16	(0.76-1.7 8)	0.4 90	0.57 9	1.13	(0.84-1.5 1)	0.4 20	0.55 2	upregulated
219087_a t	ASPN	NM_017 680	1.23	(0.78-1.9 4)	0.3 80	0.48 0	1.23	(0.95-1.5 9)	0.1 20	0.31 5	upregulated
202436_s _at	CYP1B1	AU1448 55	1.66	(1.02-2.6 8)	0.0 41	0.16 3	1.21	(0.96-1.5 2)	0.1 00	0.31	upregulated
229479_a t	LOC64632 4	Al73913 2	1.43	(0.95-2.1 5)	0.0 85	0.20 1	1.22	(0.97-1.5 3)	0.0 88	0.31 3	upregulated
230175_s _at	DCBLD2	AA8056 33	2.30	(1.22-4.3 2)	0.0 10	0.12 0	1.31	(0.90-1.9 1)	0.1 60	0.33 9	upregulated
201125_s _at	ITGB5	NM_002 213	2.41	(0.83-7.0 4)	0.11 0	0.21 6	1.63	(0.85-3.1 1)	0.1 40	0.33 1	upregulated
228176_a t	C9orf47	AA5348 17	1.17	(0.51-2.6 9)	0.7 20	0.75 7	1.73	(0.94-3.1 9)	0.0 79	0.31 3	upregulated
228224_a	PRELP	AA5731 40	1.20	(0.81-1.7 7)	0.3 70	0.47 1	1.13	(0.92-1.3 9)	0.2 30	0.38	upregulated
224396_s _at	ASPN	AF3168 24	1.10	(0.78-1.5 4)	0.6 00	0.67 0	1.11	(0.93-1.3 3)	0.2 50	0.39	upregulated
229669_a t	LOC33926 0	AA1669 65	1.69	(0.68-4.2 1)	0.2 60	0.36 2	0.97	(0.66-1.4 2)	0.8 70	0.90 9	upregulated

228335_a	CLDN11	AW2642 04	1.34	(0.79-2.2 5)	0.2 80	0.38	0.97	(0.74-1.2 6)	0.8 10	0.86	upregulated
218718_a	PDGFC	NM_016 205	1.48	(0.67-3.2 8)	0.3 30	0.43	0.99	(0.67-1.4 7)	0.9 70	0.99	upregulated
203640_a	MBNL2	BE3284 96	4.30	(1.44-12. 80)	0.0 09	0.12 0	1.77	(0.83-3.7 7)	0.1 40	0.33 1	upregulated
205422_s _at	ITGBL1	NM_004 791	1.24	(0.83-1.8 5)	0.2 90	0.38 7	1.08	(0.90-1.3 1)	0.4 00	0.53 4	upregulated
213352_a t	TMCC1	AB0183 22	9.00	(2.15-37. 72)	0.0 03	0.12 0	0.99	(0.39-2.4 9)	0.9 80	0.99	upregulated
214927_a t	ITGBL1	AL35905 2	1.71	(0.92-3.1 7)	0.0 87	0.20 3	1.15	(0.85-1.5 8)	0.3 70	0.50 3	upregulated
217949_s _at	VKORC1	NM_024 006	3.39	(0.74-15. 48)	0.11 0	0.21 6	1.55	(0.81-2.9 5)	0.1 80	0.36 2	upregulated
205713_s _at	COMP	NM_000 095	1.21	(0.87-1.6 7)	0.2 50	0.35 7	1.13	(0.93-1.3 6)	0.2 10	0.37 2	upregulated
231317_a t	TSNARE1	Al74177 9	1.36	(0.82-2.2 5)	0.2 30	0.34 7	1.04	(0.78-1.3 9)	0.7 80	0.85 9	upregulated
227112_a t	TMCC1	AW2700 37	5.54	(1.69-18. 21)	0.0 05	0.12	0.75	(0.26-2.1 5)	0.5 90	0.69 2	upregulated
204619_s _at	VCAN	BF5902 63	1.53	(0.83-2.8 0)	0.1 70	0.28	1.22	(0.88-1.6 7)	0.2 30	0.38	upregulated
203083_a t	THBS2	NM_003 247	1.42	(0.86-2.3 6)	0.1 70	0.28 0	1.26	(0.95-1.6 6)	0.11 0	0.31 5	upregulated
235408_x _at	ZNF117	AW0586 73	1.27	(0.46-3.4 8)	0.6 40	0.70 6	1.26	(0.74-2.1 2)	0.3 90	0.52 5	upregulated
222379_a t	KCNE4	Al00271 5	2.07	(0.88-4.8 9)	0.0 95	0.21	1.48	(1.05-2.0 9)	0.0 25	0.27 8	upregulated
227566_a t	HNT	AW0855 58	1.62	(0.93-2.8 1)	0.0 89	0.20 4	1.22	(0.91-1.6 5)	0.1 80	0.36 2	upregulated
226930_a t	FNDC1	Al34595 7	1.06	(0.67-1.6 7)	0.8 00	0.83 6	1.18	(0.92-1.5 2)	0.2 00	0.37 2	upregulated
228850_s _at	SLIT2	Al96330 4	0.79	(0.54-1.1 6)	0.2 40	0.35 6	1.10	(0.75-1.6 0)	0.6 30	0.72 8	upregulated
209581_a t	HRASLS3	BC0013 87	2.55	(1.25-5.1 9)	0.0 10	0.12 0	1.16	(0.86-1.5 6)	0.3 40	0.48 2	upregulated
226237_a t	COL8A1	AL35906 2	1.30	(0.80-2.1 3)	0.2 90	0.38 7	1.21	(0.91-1.6 1)	0.2 00	0.37 2	upregulated
217428_s _at	COL10A1	X98568	1.41	(0.93-2.1 3)	0.11 0	0.21 6	1.20	(0.95-1.5 1)	0.1 30	0.33 1	upregulated
212464_s _at	FN1	X02761	1.47	(0.84-2.5 9)	0.1 80	0.29	1.52	(1.04-2.2 2)	0.0 31	0.28 1	upregulated
226137_a t	ZFHX3	Al28875 9	1.61	(0.38-6.7 9)	0.5 20	0.60 1	1.24	(0.57-2.7 0)	0.5 90	0.69 2	upregulated

205941_s _at	COL10A1	Al37600 3	1.61	(1.01-2.5 4)	0.0 43	0.16 3	1.20	(0.95-1.5 2)	0.1 20	0.31 5	upregulated
1557080_ s_at	ITGBL1	Al75314 3	1.11	(0.64-1.9 5)	0.7 10	0.75 1	1.08	(0.84-1.4 1)	0.5 50	0.66 4	upregulated
202435_s _at	CYP1B1	AU1545 04	1.59	(0.87-2.9 1)	0.1 30	0.24	1.25	(0.96-1.6 2)	0.1 00	0.31 3	upregulated
213351_s _at	TMCC1	AB0183 22	3.66	(0.98-13. 69)	0.0 54	0.16 3	0.90	(0.40-1.9 9)	0.7 90	0.86 4	upregulated
208626_s _at	VAT1	BC0019 13	2.52	(1.09-5.8 6)	0.0 31	0.15 8	1.77	(1.03-3.0 2)	0.0 38	0.28 3	upregulated
210511_s _at	INHBA	M13436	1.51	(0.91-2.5 1)	0.11 0	0.21 6	1.26	(0.97-1.6 3)	0.0 81	0.31 3	upregulated
201162_a t	IGFBP7	NM_001 553	1.28	(0.59-2.8 0)	0.5 30	0.60 4	1.28	(0.86-1.9 1)	0.2 20	0.38	upregulated
211709_s _at	CLEC11A	BC0058 10	1.32	(0.65-2.7 1)	0.4 40	0.53 9	1.23	(0.84-1.8 1)	0.2 90	0.42 6	upregulated
200665_s _at	SPARC	NM_003 118	1.85	(0.74-4.6 5)	0.1 90	0.29 8	1.69	(0.98-2.9 1)	0.0 59	0.31 3	upregulated
205381_a t	LRRC17	NM_005 824	1.76	(0.82-3.8 1)	0.1 50	0.26 3	1.19	(0.77-1.8 3)	0.4 40	0.56 0	upregulated
211597_s _at	НОР	AB0594 08	1.93	(1.00-3.7 2)	0.0 51	0.16 3	1.20	(0.86-1.6 8)	0.2 90	0.42 6	upregulated
204468_s _at	TIE1	NM_005 424	0.80	(0.54-1.1 7)	0.2 50	0.35 7	1.37	(0.97-1.9 4)	0.0 73	0.31 3	upregulated
37022_at	PRELP	U41344	1.34	(0.57-3.1 0)	0.5 00	0.58 6	1.13	(0.77-1.6 7)	0.5 40	0.65 7	upregulated
227121_a t	N/A	BF4760 76	1.77	(0.67-4.6 8)	0.2 50	0.35 7	1.43	(0.75-2.7 4)	0.2 80	0.41 9	upregulated
211071_s _at	MLLT11	BC0064 71	2.31	(0.90-5.9 1)	0.0 82	0.19 7	1.29	(0.69-2.4 1)	0.4 30	0.55 2	upregulated
226497_s _at	FLT1	AA1496 48	2.42	(0.73-8.0 6)	0.1 50	0.26 3	1.86	(1.17-2.9 6)	0.0 09	0.27 8	upregulated
210517_s _at	AKAP12	AB0034 76	1.63	(1.04-2.5 6)	0.0 32	0.15 8	1.53	(1.10-2.1 4)	0.0 13	0.27 8	upregulated
201150_s _at	TIMP3	NM_000 362	1.47	(0.78-2.7 6)	0.2 30	0.34 7	1.26	(0.86-1.8 5)	0.2 40	0.39	upregulated
212667_a	SPARC	AL57592 2	1.27	(0.65-2.4 8)	0.4 80	0.57 1	1.32	(0.90-1.9 3)	0.1 60	0.33 9	upregulated
224911_s _at	DCBLD2	AA7227 99	2.66	(1.69-4.1 8)	0.0 00	0.00 4	1.55	(1.11-2.1 6)	0.0 10	0.27 8	upregulated
236297_a t	N/A	Al42081 7	0.96	(0.43-2.1 4)	0.9 10	0.92 7	1.13	(0.73-1.7 5)	0.5 80	0.69 0	upregulated
211719_x _at	FN1	BC0058 58	1.53	(0.82-2.8 7)	0.1 90	0.29 8	1.51	(0.99-2.3 1)	0.0 57	0.31	upregulated

216442_x _at	FN1	AK0267 37	1.56	(0.85-2.8 8)	0.1 50	0.26	1.58	(1.02-2.4 4)	0.0 39	0.28	upregulated
210004_a	OLR1	AF0357 76	1.13	(0.72-1.7 6)	0.6 00	0.67 0	1.23	(0.95-1.5 8)	0.1 20	0.31 5	upregulated
209894_a t	LEPR	U50748	0.77	(0.33-1.8 1)	0.5 50	0.62	1.33	(0.84-2.1 0)	0.2 30	0.38	upregulated
223279_s _at	UACA	AF3229 16	2.93	(0.99-8.6 6)	0.0 52	0.16 3	1.74	(0.95-3.1 9)	0.0 75	0.31 3	upregulated
1553530_ a_at	ITGB1	NM_033 669	1.63	(0.48-5.5 8)	0.4 40	0.53 9	2.64	(1.22-5.7 1)	0.0 13	0.27 8	upregulated
210495_x _at	FN1	AF1300 95	1.61	(0.84-3.0 9)	0.1 50	0.26 3	1.62	(1.03-2.5 6)	0.0 38	0.28 3	upregulated
225566_a t	NRP2	Al81972 9	1.21	(0.75-1.9 5)	0.4 30	0.53 5	1.34	(0.97-1.8 5)	0.0 80	0.31 3	upregulated
204589_a t	NUAK1	NM_014 840	1.83	(0.69-4.8 8)	0.2 20	0.33 8	1.22	(0.81-1.8 6)	0.3 40	0.48 2	upregulated
210809_s _at	POSTN	D13665	1.45	(0.83-2.5 5)	0.1 90	0.29 8	1.33	(0.93-1.9 0)	0.1 20	0.31 5	upregulated
202133_a t	WWTR1	BF6743 49	2.08	(1.05-4.1 4)	0.0 37	0.15 9	1.65	(1.06-2.5 6)	0.0 27	0.27 8	upregulated
219179_a t	DACT1	NM_016 651	0.82	(0.47-1.4 2)	0.4 70	0.56 3	0.82	(0.49-1.3 5)	0.4 30	0.55 2	upregulated
213413_a t	STON1	BG4341 74	1.07	(0.56-2.0 5)	0.8 40	0.87 2	1.28	(0.85-1.9 2)	0.2 30	0.38	upregulated
219922_s _at	LTBP3	NM_021 070	1.84	(0.77-4.3 8)	0.1 70	0.28	1.37	(0.85-2.2 1)	0.2 00	0.37 2	upregulated
204223_a	PRELP	NM_002 725	0.99	(0.57-1.7 1)	0.9 60	0.96 6	1.12	(0.83-1.5 0)	0.4 60	0.57 2	upregulated
225450_a t	AMOTL1	Al43383 1	1.29	(0.67-2.4 7)	0.4 50	0.54 3	1.26	(0.78-2.0 5)	0.3 50	0.48 8	upregulated
201560_a t	CLIC4	NM_013 943	2.21	(0.87-5.6 4)	0.0 97	0.21	1.61	(0.94-2.7 3)	0.0 80	0.31 3	upregulated
210078_s _at	KCNAB1	L39833	0.85	(0.56-1.2 9)	0.4 50	0.54 3	1.05	(0.71-1.5 4)	0.8 10	0.86 9	upregulated
1555778_ a_at	POSTN	AY1406 46	1.28	(0.82-2.0 1)	0.2 80	0.38 4	1.26	(0.95-1.6 6)	0.11 0	0.31 5	upregulated
213125_a t	OLFML2B	AW0075 73	1.55	(0.79-3.0 3)	0.2 00	0.31	1.37	(0.97-1.9 5)	0.0 76	0.31 3	upregulated
213656_s _at	KLC1	BF5935 94	0.75	(0.22-2.6 2)	0.6 50	0.70 6	2.66	(1.13-6.2 7)	0.0 25	0.27 8	upregulated
227529_s _at	AKAP12	BF51127 6	1.38	(0.98-1.9 5)	0.0 65	0.16 3	1.41	(1.07-1.8 5)	0.0 15	0.27 8	upregulated
225021_a t	ZNF532	AA8614 16	2.29	(1.05-4.9 7)	0.0 37	0.15 9	1.89	(1.11-3.2 4)	0.0 20	0.27 8	upregulated

214770_a t	MSR1	Al29923 9	1.67	(0.81-3.4 7)	0.1 70	0.28	1.04	(0.77-1.4 1)	0.7 80	0.85 9	upregulated
209747_a	TGFB3	J03241	1.69	(0.68-4.2 3)	0.2 60	0.36	1.42	(0.90-2.2 5)	0.1 40	0.33 1	upregulated
212488_a t	COL5A1	N30339	1.36	(0.76-2.4 4)	0.2 90	0.38 7	1.37	(0.96-1.9 7)	0.0 83	0.31 3	upregulated
225381_a t	LOC39995 9	AW1622 10	1.28	(0.79-2.0 6)	0.3 20	0.42	1.29	(0.90-1.8 5)	0.1 60	0.33 9	upregulated
202766_s _at	FBN1	NM_000 138	1.27	(0.72-2.2 5)	0.4 10	0.51 4	1.23	(0.89-1.7 1)	0.2 10	0.37	upregulated
203238_s _at	NOTCH3	NM_000 435	1.79	(0.85-3.8 0)	0.1 30	0.24	1.85	(1.16-2.9 6)	0.0 10	0.27 8	upregulated
226364_a t	HIP1	AU1450 49	2.06	(0.87-4.9 2)	0.1 00	0.21	1.58	(0.84-2.9 6)	0.1 50	0.33 9	upregulated
226997_a t	ADAMTS1 2	W74476	1.16	(0.61-2.2 4)	0.6 50	0.70 6	1.26	(0.83-1.9 2)	0.2 80	0.41 9	upregulated
227530_a t	AKAP12	BF51127 6	1.43	(0.93-2.2 0)	0.1 00	0.21 2	1.52	(1.08-2.1 3)	0.0 16	0.27 8	upregulated
225946_a t	RASSF8	BG4845 52	1.86	(0.97-3.6 0)	0.0 64	0.16 3	1.30	(0.82-2.0 6)	0.2 60	0.40	upregulated
1558027_ s_at	PRKAB2	AL55200 1	1.09	(0.39-3.0 7)	0.8 70	0.89	2.91	(1.31-6.4 3)	0.0 08	0.27 8	upregulated
207076_s _at	ASS1	NM_000 050	0.34	(0.15-0.7 8)	0.01 1	0.12 0	1.34	(0.86-2.0 9)	0.2 00	0.37 2	downregulat ed
224240_s _at	CCL28	AF2665 04	0.49	(0.24-0.9 9)	0.0 48	0.16 3	0.74	(0.49-1.1 3)	0.1 60	0.33 9	downregulat ed
211367_s _at	CASP1	U13699	0.56	(0.34-0.9 4)	0.0 27	0.15 7	0.72	(0.50-1.0 5)	0.0 84	0.31 3	downregulat ed
209374_s _at	IGHM	BC0018 72	0.72	(0.55-0.9 4)	0.0 15	0.12 9	0.90	(0.75-1.0 8)	0.2 40	0.39 1	downregulat ed
205267_a t	POU2AF1	NM_006 235	0.55	(0.33-0.8 9)	0.0 16	0.13 0	0.80	(0.57-1.1 3)	0.2 10	0.37 2	downregulat ed
205891_a t	ADORA2B	NM_000 676	1.20	(0.49-2.9 3)	0.6 90	0.74 0	0.88	(0.54-1.4 4)	0.6 10	0.71 0	downregulat ed
217378_x _at	IGKV1OR2 -108	X51887	0.82	(0.66-1.0 2)	0.0 80	0.19 7	0.91	(0.79-1.0 5)	0.2 10	0.37 2	downregulat ed
214836_x _at	IGKC	BG5362 24	0.68	(0.46-0.9 9)	0.0 45	0.16 3	0.79	(0.58-1.0 8)	0.1 40	0.33 1	downregulat ed
218096_a t	AGPAT5	NM_018 361	0.74	(0.28-1.9 3)	0.5 30	0.60 4	0.75	(0.47-1.2 2)	0.2 50	0.39 2	downregulat ed
215949_x _at	IGHM	BF0026 59	0.74	(0.55-1.0 1)	0.0 57	0.16 3	0.92	(0.74-1.1 3)	0.4 20	0.55 2	downregulat ed
226147_s _at	PIGR	AA8380 75	0.80	(0.67-0.9 5)	0.0 13	0.12 9	0.99	(0.85-1.1 4)	0.8 40	0.88 3	downregulat ed

202659_a	PSMB10	NM_002 801	0.39	(0.16-0.9 9)	0.0 49	0.16 3	1.07	(0.55-2.0 9)	0.8 40	0.88	downregulat ed
214916_x _at	IL8	BG3405 48	0.72	(0.57-0.9 1)	0.0 06	0.12	0.86	(0.72-1.0 3)	0.1 00	0.31 3	downregulat ed
211881_x _at	IGLJ3	AB0143 41	0.65	(0.39-1.0 8)	0.0 93	0.21 1	0.80	(0.60-1.0 6)	0.1 30	0.33 1	downregulat ed
216576_x _at	NTN2L	AF1035 29	0.74	(0.58-0.9 4)	0.0 15	0.12 9	0.88	(0.75-1.0 4)	0.1 50	0.33 9	downregulat ed
209970_x _at	CASP1	M87507	0.50	(0.28-0.9 1)	0.0 22	0.14 9	0.64	(0.40-1.0 4)	0.0 73	0.31	downregulat ed
216207_x _at	IGKV1D-1 3	AW4081 94	0.70	(0.48-1.0 2)	0.0 61	0.16 3	0.83	(0.65-1.0 7)	0.1 50	0.33 9	downregulat ed
205049_s _at	CD79A	NM_001 783	0.59	(0.35-0.9 7)	0.0 38	0.15 9	0.73	(0.50-1.0 8)	0.1 20	0.31 5	downregulat ed
211645_x _at	N/A	M85256	0.78	(0.62-0.9 8)	0.0 30	0.15 8	0.88	(0.74-1.0 4)	0.1 40	0.33 1	downregulat ed
234366_x _at	IGL@	AF1035 91	0.66	(0.41-1.0 8)	0.0 99	0.21	0.77	(0.56-1.0 4)	0.0 93	0.31 3	downregulat ed
217480_x _at	HLA-C	M20812	0.69	(0.48-0.9 9)	0.0 47	0.16 3	0.82	(0.65-1.0 3)	0.0 95	0.31 3	downregulat ed
238750_a t	N/A	AW0835 76	0.73	(0.53-1.0 1)	0.0 61	0.16 3	0.88	(0.67-1.1 6)	0.3 70	0.50 3	downregulat ed
217157_x _at	N/A	AF1035 30	0.69	(0.47-1.0 2)	0.0 60	0.16 3	0.76	(0.58-1.0 0)	0.0 50	0.31 3	downregulat ed
209208_a t	MPDU1	AF0597 52	0.82	(0.30-2.2 2)	0.7 00	0.74 6	0.80	(0.42-1.5 2)	0.4 90	0.60 5	downregulat ed
211368_s _at	CASP1	U13700	0.61	(0.36-1.0 3)	0.0 64	0.16 3	0.66	(0.43-1.0 0)	0.0 50	0.31 3	downregulat ed
214440_a t	NAT1	NM_000 662	0.44	(0.19-1.0 5)	0.0 65	0.16 3	0.63	(0.38-1.0 6)	0.0 82	0.31 3	downregulat ed
211366_x _at	CASP1	U13698	0.41	(0.21-0.8 1)	0.0 10	0.12	0.71	(0.44-1.1 5)	0.1 60	0.33 9	downregulat ed
238725_a t	IRF1	AW3925 51	0.64	(0.40-1.0 2)	0.0 61	0.16 3	1.20	(0.75-1.9 4)	0.4 50	0.56 9	downregulat ed
234884_x _at	N/A	L21961	0.73	(0.52-1.0 2)	0.0 65	0.16 3	0.79	(0.58-1.0 6)	0.11 0	0.31 5	downregulat ed
221286_s _at	MGC2950 6	NM_016 459	0.78	(0.57-1.0 7)	0.1 30	0.24 1	0.82	(0.66-1.0 2)	0.0 70	0.31 3	downregulat ed
205476_a t	CCL20	NM_004 591	0.95	(0.75-1.2 1)	0.6 80	0.73 4	0.91	(0.70-1.1 9)	0.5 00	0.61 3	downregulat ed
212592_a t	IGJ	AV7332 66	0.72	(0.57-0.9 2)	0.0 07	0.12 0	0.84	(0.71-0.9 9)	0.0 40	0.28 3	downregulat ed
204213_a t	PIGR	NM_002 644	0.69	(0.49-0.9 6)	0.0 28	0.15 7	0.97	(0.79-1.1 7)	0.7 20	0.81 5	downregulat ed

226499_a t	NRARP	W72331	0.59	(0.30-1.1 7)	0.1 30	0.24 1	0.86	(0.51-1.4 4)	0.5 60	0.67 1	downregulat ed
214214_s _at	C1QBP	AU1518 01	1.30	(0.42-4.0 4)	0.6 50	0.70 6	0.63	(0.30-1.3 3)	0.2 30	0.38	downregulat ed
211798_x _at	IGLJ3	AB0017 33	0.74	(0.49-1.1 3)	0.1 60	0.27 7	0.81	(0.62-1.0 4)	0.1 00	0.31	downregulat ed
215176_x _at	NTN2L	AW4048 94	0.81	(0.65-1.0 1)	0.0 56	0.16 3	0.86	(0.72-1.0 3)	0.11 0	0.31 5	downregulat ed
209397_a t	ME2	BC0001 47	0.60	(0.28-1.2 9)	0.1 90	0.29 8	0.74	(0.33-1.6 4)	0.4 60	0.57 2	downregulat ed
206641_a t	TNFRSF1 7	NM_001 192	0.72	(0.54-0.9 5)	0.0 22	0.14 9	0.89	(0.74-1.0 7)	0.2 10	0.37 2	downregulat ed
216557_x _at	IFI6	U92706	0.69	(0.45-1.0 5)	0.0 81	0.19 7	0.86	(0.66-1.1 2)	0.2 70	0.41	downregulat ed
221651_x _at	IGKC	BC0053 32	0.70	(0.48-1.0 1)	0.0 55	0.16 3	0.78	(0.59-1.0 3)	0.0 85	0.31	downregulat ed
229568_a t	MOBKL2B	Al69287 8	0.29	(0.10-0.9 1)	0.0 34	0.15 8	0.65	(0.31-1.3 6)	0.2 50	0.39 2	downregulat ed
219727_a t	DUOX2	NM_014 080	0.89	(0.69-1.1 4)	0.3 50	0.44 9	0.89	(0.74-1.0 8)	0.2 50	0.39	downregulat ed
217281_x _at	IL8	AJ23938 3	0.76	(0.62-0.9 4)	0.01 1	0.12	0.90	(0.78-1.0 5)	0.1 90	0.37 2	downregulat ed
221671_x _at	IGKC	M63438	0.72	(0.51-1.0 1)	0.0 56	0.16 3	0.79	(0.63-0.9 8)	0.0 34	0.28 3	downregulat ed
215946_x _at	CTA-246H 3.1	AL02232 4	0.60	(0.38-0.9 5)	0.0 28	0.15 7	0.74	(0.57-0.9 7)	0.0 29	0.27 8	downregulat ed
214777_a t	N/A	BG4828 05	0.76	(0.63-0.9 2)	0.0 04	0.12	0.89	(0.76-1.0 3)	0.1 00	0.31	downregulat ed
209040_s _at	PSMB8	U17496	0.59	(0.25-1.4 2)	0.2 40	0.35 6	0.89	(0.47-1.6 9)	0.7 30	0.82	downregulat ed
216542_x _at	IGHA1	AJ27535 5	0.66	(0.36-1.2 0)	0.1 70	0.28	0.74	(0.50-1.0 8)	0.1 20	0.31 5	downregulat ed
224027_a t	CCL28	AF11038 4	0.65	(0.49-0.8 6)	0.0 03	0.12 0	1.06	(0.81-1.3 7)	0.6 80	0.77 5	downregulat ed
229070_a t	C6orf105	AA4703 69	0.75	(0.59-0.9 7)	0.0 30	0.15 8	0.91	(0.76-1.0 9)	0.3 20	0.46 2	downregulat ed
211641_x _at	N/A	L06101	0.59	(0.37-0.9 3)	0.0 23	0.15 0	0.69	(0.49-0.9 9)	0.0 43	0.29 2	downregulat ed
204301_a t	KBTBD11	NM_014 867	1.03	(0.55-1.9 2)	0.9 30	0.94 2	0.96	(0.55-1.6 8)	0.8 90	0.91 8	downregulat ed
221841_s _at	KLF4	BF5140 79	0.55	(0.32-0.9 6)	0.0 36	0.15 9	1.27	(0.84-1.9 2)	0.2 60	0.40 0	downregulat ed
211647_x _at	IGHG1	L14454	0.79	(0.53-1.1 8)	0.2 50	0.35 7	0.78	(0.58-1.0 5)	0.0 96	0.31 3	downregulat ed

235350_a t	C4orf19	Al93558 6	0.43	(0.23-0.7 8)	0.0 06	0.12	1.09	(0.64-1.8 5)	0.7 50	0.83 7	downregulat ed
216829_a t	NTN2L	X72475	0.73	(0.58-0.9 3)	0.01 1	0.12 0	0.92	(0.78-1.0 9)	0.3 50	0.48 8	downregulat ed
203110_a t	PTK2B	U43522	0.73	(0.47-1.1 2)	0.1 50	0.26 3	1.07	(0.81-1.4 1)	0.6 50	0.74 6	downregulat ed
214433_s _at	SELENBP 1	NM_003 944	0.68	(0.45-1.0 2)	0.0 61	0.16 3	0.72	(0.54-0.9 6)	0.0 23	0.27 8	downregulat ed
226319_s _at	THOC4	AF0470 02	1.68	(0.63-4.5 2)	0.3 00	0.39 8	1.07	(0.60-1.9 1)	0.8 10	0.86 9	downregulat ed
227014_a	ASPHD2	BE5508 81	0.53	(0.25-1.1 4)	0.11 0	0.21 6	1.56	(0.99-2.4 6)	0.0 55	0.31 3	downregulat ed
209569_x _at	D4S234E	NM_014 392	0.39	(0.17-0.8 8)	0.0 24	0.15 0	0.66	(0.36-1.2 3)	0.1 90	0.37 2	downregulat ed
225667_s _at	FAM84A	Al60110 1	0.69	(0.44-1.0 8)	0.11 0	0.21 6	0.68	(0.52-0.8 8)	0.0 03	0.27 8	downregulat ed
211635_x _at	IGHV1-69	M24670	0.75	(0.58-0.9 9)	0.0 40	0.16 3	0.94	(0.79-1.1 0)	0.4 30	0.55 2	downregulat ed
205242_a	CXCL13	NM_006 419	0.84	(0.67-1.0 4)	0.1 20	0.23	1.00	(0.85-1.1 8)	1.0 00	1.00	downregulat ed
219148_a t	PBK	NM_018 492	1.01	(0.48-2.1 3)	0.9 70	0.97 0	0.96	(0.65-1.4 1)	0.8 20	0.87 4	downregulat ed
219450_a t	C4orf19	NM_018 302	0.57	(0.34-0.9 5)	0.0 33	0.15 8	1.05	(0.59-1.8 6)	0.8 80	0.91 4	downregulat ed
209138_x _at	IGL@	M87790	0.72	(0.54-0.9 5)	0.0 18	0.13 3	0.81	(0.67-0.9 8)	0.0 29	0.27 8	downregulat ed
214677_x _at	IGLJ3	X57812	0.71	(0.53-0.9 4)	0.0 18	0.13 3	0.78	(0.64-0.9 6)	0.0 20	0.27 8	downregulat ed
1555779_ a_at	CD79A	M74721	0.93	(0.43-1.9 9)	0.8 50	0.87 7	0.73	(0.45-1.1 6)	0.1 80	0.36 2	downregulat ed
210885_s _at	TRIM15	AF2201 33	0.70	(0.48-1.0 1)	0.0 57	0.16 3	1.15	(0.86-1.5 3)	0.3 60	0.49 7	downregulat ed
216430_x _at	IGL@	AF0435 86	0.68	(0.50-0.9 3)	0.0 15	0.12 9	0.90	(0.75-1.0 9)	0.3 00	0.43 7	downregulat ed
225053_a	CNOT7	W94952	1.61	(0.38-6.9 2)	0.5 20	0.60 1	1.00	(0.45-2.2	0.9 90	0.99 6	downregulat ed
204279_a t	PSMB9	NM_002 800	0.75	(0.45-1.2 4)	0.2 60	0.36 2	1.01	(0.66-1.5 4)	0.9 80	0.99	downregulat ed

**Supplementary Table S5.** Three significant gene ontology (GO) annotation clusters and two significant KEGG pathways identified for the 128 metastasis-associated genes (163 probe sets) identified in colorectal cancer.

Analysis was performed using the Functional Annotation Clustering tool on the Database for Annotation, Visualization and Integrated Discovery (DAVID). GO annotation levels one to three were considered. *P*-values were adjusted using the Benjamini-Hochberg False Discovery Rate multiple testing correction.

## A. Genes up-regulated in metastatic cancers as compared to early-stage cancers

GO Annotation Cluster 1	GO Annotation	Enrichment Score: 5.81	Cou nt	P value
	GOTERM_BP_1	developmental process	33	5.40E-0 8
C9orf47, CLDN11, CLIC4,	GOTERM_BP_2	multicellular organismal development	25	4.90E-0 5
COL10A1, COL8A1, COMP, CYP1B1, DACT1, DCBLD2, FBN1, FLT1, HIP1, HMCN1, HOP,	GOTERM_BP_2	anatomical structure development	23	1.30E-0 4
IGFBP7, INHBA, ITGB1, ITGB5, LEPR, LTBP3, NOTCH3, NRP2, OLR1, PDGFC, POSTN, PRELP,	GOTERM_BP_3	organ development	17	6.00E-0 3
SLIT2, SPARC, SPP1, TGFB3, TIE1, TIMP3, UACA, VAT1, VCAN, WWTR1	, TGFB3, multicellular organismal		29	1.40E-0 4
VOAN, WWIRI	GOTERM_BP_3	system development	19	1.10E-0 2
GO Annotation Cluster 2	GO Annotation	Enrichment Score: 5.79	Cou nt	P value
CLDN11, CLEC11A, COL10A1, COL5A1, COL5A1, COL8A1, COMP, FBN1,	GOTERM_CC_3	proteinaceous extracellular matrix	14	1.20E-0 7
FLT1, FN1, HIP1, HMCN1, IGFBP7, INHBA, LTBP3, PDGFC, POSTN, PRELP, SLIT2, SPARC,	GOTERM_CC_2	proteinaceous extracellular matrix	14	3.10E-0 8
SPP1, THBS2, TIMP3, UACA, VCAN	GOTERM_CC_1	extracellular matrix	14	9.60E-0 9
	GOTERM_CC_1	extracellular region	22	1.00E-0 7
	GOTERM_CC_2	extracellular region part	17	1.50E-0 6

<sup>\*</sup>GenBank accession number

	GOTERM_CC_1	extracellular region part	17	2.70E-0 7
	GOTERM_CC_2	extracellular matrix part	7	1.10E-0 4
	GOTERM_CC_1	extracellular matrix part	7	1.90E-0 5
	GOTERM_CC_3	basement membrane	5	2.80E-0 2
	GOTERM_CC_2	basement membrane	5	3.20E-0 3
	GOTERM_MF_1	structural molecule activity	10	3.00E-0 2
	GOTERM_CC_3	collagen	3	7.30E-0 1
	GOTERM_CC_2	collagen	3	1.50E-0 1
KEGG Pathway Cluster 1	KEGG Pathway		Cou nt	P value
COL5A1, FN1, FNDC1, ITGB1, ITGB5, SPP1, THBS2	ECM-receptor interaction		7	1.80E-0 3
KEGG Pathway Cluster 2	KEGG Pathway		Cou nt	P value
COL5A1, COMP, FLT1, FN1, ITGB1, ITGB5, PDGFC, SPP1, THBS2	Focal adhesion		9	1.20E-0 3

## B. Genes down-regulated in metastatic cancers as compared to early-stage cancers

GO Annotation Cluster 1	GO Annotation	Enrichment Score: 13.97	Cou nt	P value
	GOTERM_BP_2	immune response	24	6.20E-1 6
ADORA2B, C1QBP, CCL20, CCL28, CD79A, CTA-246H3.1, CXCL13, DUOX2, IFI6, IGHA1,	GOTERM_BP_1	immune system process	24	1.40E-1 4
IGHG1, IGHM, IGH@, IGJ, IGKC, IGK@, IGL@, IGLJ3, IL8, POU2AF1, PSMB10, PSMB8,	GOTERM_MF_2	antigen binding	13	3.40E-1 3
PSMB9, PTK2B, TNFRSF17, AW083576*, AW392551*	GOTERM_BP_1	response to stimulus	27	1.60E-0 8

**Supplementary Fig S1.** Overall and class-specific misclassification errors for ten-fold cross-validation PAM with increasing values of centroid shrinkage for 86 stage A and 93 stage D colorectal cancers from this study and expO classified using our set of 128 metastasis-associated genes (163 probe sets).

Increasing values of centroid shrinkage are designed to progressively eliminate noisy genes. For our samples, classification accuracy for cross-validation did not improve with increasing shrinkage thresholds. Misclassification errors remained consistently low at approximately 25% for threshold values between zero and two, and rose with further increases in centroid shrinkage. Our initial 163 probe set therefore appeared to be a robust PAM classifier for our primary stage A and stage D cancers with some redundancy in information content. Redundancy is a feature desired for robust microarray-based classification.

**Supplementary Fig S2.** Prediction probabilities for the classification of (**A**) 95 stage B and (**B**) 93 stage C colorectal cancers into stage A- and stage D-like types using Prediction Analysis of Microarrays (PAM).

Predictions for single samples were made against a common reference set of stage A and stage D CRCs. Prior (expected) five-year recurrence probabilities were set as 20% for stage B and 40% for stage C patients based on relapse rates observed in clinical practice. The dashed line shows the prediction probability cut-off set at 90%.

**Supplementary Fig S3.** PAM-based prognosis prediction for stage B and C colorectal cancer patients based on metastasis-associated genes.

Disease-free survival curves generated using our 128-gene PAM classifier show a significant difference in outcome. For single-sample PAM classification, prior (expected) six-year recurrence probabilities were set as 20% for stage B and 40% for stage C patients based on relapse rates observed in clinical practice (21). Class predictions with a >90% were scored.

**Supplementary Fig S4.** Representative examples of haematoxylin & eosin stained tissue sections from colorectal cancers showing low, moderate and high average density of mononuclear chronic inflammatory cells.

The average density of mononuclear chronic inflammatory cells was scored within tumor areas comprising more than 60% of neoplastic cells as outlined; areas of adenoma, ulceration and necrosis were excluded from the analysis.